Results 21 to 30 of about 602,416 (352)

A rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo

Science Advances, 2023
Triple-negative breast cancer (TNBC) remains the most lethal form of breast cancer, and effective targeted therapeutics are in urgent need to improve the poor prognosis of TNBC patients.
P. Guo, Jing Huang, B. Zhu, Andrew C Huang, Lingxiao Jiang, J. Fang, M. Moses   +6 more
semanticscholar   +1 more source

Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate

Pharmaceutics, 2022
As one of the major therapeutic options for cancer treatment, chemotherapy has limited selectivity against cancer cells. Consequently, this therapeutic strategy offers a small therapeutic window with potentially high toxicity and thus limited efficacy of
Rotimi Sheyi, B. G. de la Torre, F. Albericio   +2 more
semanticscholar   +1 more source

Anti-VEGFR2 F(ab′)2 drug conjugate promotes renal accumulation and glomerular repair in diabetic nephropathy

Nature Communications, 2023
Poor renal distribution of antibody-based drugs is the key factor contributing to low treatment efficiency for renal diseases and side effects. Here, we prepare F(ab′)2 fragmented vascular endothelial growth factor receptor 2 antibody (anti-VEGFR2 (F(ab′)
Di Liu, Yanling Song, Hui Chen, Yuchan You, Luwen Zhu, Jucong Zhang, Xinyi Xu, Jiahao Hu, Xiajie Huang, Xiaochuan Wu, Xiaoling Xu, Saiping Jiang, Yongzhong Du   +12 more
doaj   +1 more source

New Life of Topoisomerase I Inhibitors as Antibody Drug Conjugate Warheads.

Clinical Cancer Research, 2023
Antibody drug conjugates (ADCs) allow the delivery of cytotoxic chemotherapeutic agents to tumors. Two ADC delivering topoisomerase I (TOP1) poisons (Enhertu and Trodelvy) have recently been FDA-approved for Her2- and Trop2-expressing solid tumors.
Y. Pommier, Anish Thomas
semanticscholar   +1 more source

Datopotamab Deruxtecan, a Novel TROP2-directed Antibody–drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells

Molecular Cancer Therapeutics, 2021
Trophoblast cell surface antigen 2 (TROP2) is highly expressed on various epithelial tumors and correlates with poor prognosis. We developed the novel TROP2-directed antibody–drug conjugate (ADC), datopotamab deruxtecan (Dato-DXd, DS-1062a), with a ...
D. Okajima, Satoru Yasuda, T. Maejima, Tsuyoshi Karibe, Ken Sakurai, T. Aida, Tadashi Toki, J. Yamaguchi, Michiko Kitamura, Reiko Kamei, Tomomichi Fujitani, T. Honda, T. Shibutani, Sumie Muramatsu, T. Nakada, R. Goto, S. Takahashi, M. Yamaguchi, H. Hamada, Yutaka Noguchi, M. Murakami, Yuki Abe, T. Agatsuma   +22 more
semanticscholar   +1 more source

The antibody-drug conjugate loncastuximab tesirine for the treatment of diffuse large B-cell lymphoma

Blood, 2022
In this Blood Spotlight, Calabretta and colleagues describe the mechanism of action of loncastuximab tesirine, an anti-CD19 antibody-drug conjugate. They discuss data from the first phase 1 and 2 trials of the drug in patients with relapsed or refractory
Eleonora Calabretta, M. Hamadani, C. Carlo-Stella   +2 more
semanticscholar   +1 more source

Overcoming Resistance to Anti-nectin-4 Antibody-Drug Conjugate.

Molecular Cancer Therapeutics, 2022
Antibody-drug conjugates (ADCs) represent a fast-growing drug class in oncology. However, ADCs are associated with resistance, and therapies able to overcome it are of utmost importance.
O. Cabaud, Ludovic G M Berger, E. Crompot, J. Adélaide, P. Finetti, S. Garnier, A. Guille, N. Carbuccia, A. Farina, Emilie Agavnian, M. Chaffanet, A. Gonçalves, E. Charafe-Jauffret, E. Mamessier, Daniel Birmbaum, F. Bertucci, Marc Lopez   +16 more
semanticscholar   +1 more source

ABBV-011, A Novel, Calicheamicin-Based Antibody–Drug Conjugate, Targets SEZ6 to Eradicate Small Cell Lung Cancer Tumors

Molecular Cancer Therapeutics, 2022
In the past year, four antibody–drug conjugates (ADC) were approved, nearly doubling the marketed ADCs in oncology. Among other attributes, successful ADCs optimize targeting antibody, conjugation chemistry, and payload mechanism of action.
Wolf R Wiedemeyer, Julia Gavrilyuk, Alexander Schammel, Xi Zhao, H. Sarvaiya, Marybeth Pysz, Christine Gu, Monica You, K. Isse, Theodore Sullivan, D. French, Christina Lee, Angeline T Dang, Zhaomei Zhang, M. Aujay, A. Bankovich, Philip Vitorino   +16 more
semanticscholar   +1 more source

Efficacy and Safety of ABBV‐3373, a Novel Anti–Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody–Drug Conjugate, in Adults with Moderate‐to‐Severe Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, Double‐Blind, Active‐Controlled Proof‐of‐Concept Phase IIa Trial

Arthritis & Rheumatology, 2022
To assess the efficacy and safety of ABBV‐3373, a novel antibody–drug conjugate (ADC) composed of the anti–tumor necrosis factor (anti‐TNF) monoclonal antibody adalimumab linked to a glucocorticoid receptor modulator (GRM), compared to adalimumab, in ...
F. Buttgereit, J. Aelion, B. Rojkovich, A. Zubrzycka-Sienkiewicz, Su Chen, Yang Yang, D. Arikan, Ronilda R. D’Cunha, Yinuo Pang, H. Kupper, T. Radstake, H. Amital   +11 more
semanticscholar   +1 more source

A Vaccine Against Group B Streptococcus: Recent Advances [PDF]

, 2020
Group B streptococcus (GBS) causes a high burden of neonatal and infant disease globally. Implementing a vaccine for pregnant women is a promising strategy to prevent neonatal and infant GBS disease and has been identified as a priority by the World ...
Carreras-Abad, C, Heath, PT, Le Doare, K, Ramkhelawon, L   +3 more
core   +2 more sources